Vivax Malaria

Malaria caused by PLASMODIUM VIVAX. This form of malaria is less severe than MALARIA, FALCIPARUM, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day.

Also Known As:

Networked: 1229 relevant articles (148 outcomes, 189 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Malaria
2.	Falciparum Malaria (Plasmodium falciparum Malaria)
3.	Infections
4.	Body Weight (Weight, Body)
5.	Glucosephosphate Dehydrogenase Deficiency

Experts

1.	White, Nicholas J: 50 articles (10/2021 - 05/2003)
2.	Baird, J Kevin: 36 articles (01/2022 - 10/2002)
3.	Price, Ric N: 33 articles (01/2022 - 02/2007)
4.	Lacerda, Marcus V G: 31 articles (01/2022 - 09/2008)
5.	Anstey, Nicholas M: 26 articles (01/2022 - 12/2002)
6.	Imwong, Mallika: 23 articles (10/2021 - 08/2006)
7.	Sattabongkot, Jetsumon: 22 articles (06/2022 - 11/2003)
8.	Nosten, François: 22 articles (10/2021 - 05/2003)
9.	Duparc, Stephan: 21 articles (10/2022 - 01/2011)
10.	Chu, Cindy S: 21 articles (10/2021 - 01/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vivax Malaria:

1.	Chloroquine (Aralen)FDA LinkGeneric 10/01/2014 - "Chloroquine is the first-line treatment for Plasmodium vivax malaria in most endemic countries, but resistance is increasing. " 12/01/2010 - "Chloroquine is the first-line treatment for Plasmodium vivax malaria in most parts of the world. " 01/01/2019 - "A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria." 03/01/1992 - "More ominously, a resident of the Highlands region of Papua New Guinea contracted vivax malaria which failed to be cleared by 2400 mg chloroquine base administered over 4 d. " 05/14/2019 - "This study aimed to determine therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone, southern central Ethiopia. "
2.	PrimaquineFDA Link 10/01/2002 - "Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India." 01/01/2018 - "These findings suggest a natural variability in CYP2D6-dependent metabolism of primaquine as a key determinant of therapeutic efficacy against latent P vivax malaria." 08/01/2017 - "We aimed to determine whether unsupervised primaquine was effective for preventing re-presentation to hospital with vivax malaria in southern Papua, Indonesia. " 04/01/2010 - "A 1 week course of primaquine 60 mg daily is an effective treatment of vivax malaria in this region." 07/01/2013 - "This study was designed to assess the efficacy of 8 weeks of primaquine treatment in prevention of relapse in patients with vivax malaria in south and south-east Iran by SSCP-PCR and sequencing. "
3.	Antimalarials (Antimalarial Agents)IBA 12/24/2021 - "The overall efficacy of anti-malarial drugs evaluated for the treatment of vivax malaria in Ethiopia was generally high, although there was wide-ranging degree of efficacy, which was affected by the treatment options, duration of follow-up, transmission intensity, and the confirmation procedures for recurrent parasitaemia. " 12/24/2021 - "The pooled estimate of in vivo efficacy of anti-malarial drugs against vivax malaria in Ethiopia was 97.91% (95% CI: 97.29-98.52%), with significant heterogeneity (I2 = 86%, p < 0.0001) and publication bias (Egger's test = -12.86, p < 0.001). " 08/11/2015 - "vivax malaria as per the World Health Organization's protocol of in vivo assessment of anti-malarial therapeutic efficacy. " 10/07/2021 - "Improved control of Plasmodium vivax malaria can be achieved with the discovery of new antimalarials with radical cure efficacy, including prevention of relapse caused by hypnozoites residing in the liver of patients. " 06/11/2023 - "This study aimed to help make trend predictions regarding variations the in anti-malarial drug susceptibility of Plasmodium vivax distributed in Yunnan Province and effectively implement monitoring measures on the efficacy of anti-malarial drugs for vivax malaria. "
4.	VaccinesIBA 12/22/2015 - "vivax malaria vaccines and discuss the challenges as well as directions toward the goal of developing highly efficacious vaccines against P. " 01/01/2022 - "Developing a safe and effective vaccine against vivax malaria is essential for controlling and eliminating the disease. " 01/01/2023 - "In the present study, we designed a transdermal vaccine against vivax malaria using a solid-in-oil (S/O) dispersion. " 01/01/2020 - "These studies provide new insights for the clinical management of symptomatic as well as asymptomatic individuals and the development of an efficacious vaccine for vivax malaria." 12/01/2016 - "yoelii and Plasmodium vivax malaria parasites that can be validated for further vaccine studies. "
5.	artemisinin (artemisinine)IBA 08/15/2019 - "vivax malaria, as well as the artemisinin resistance-associated Pfkelch13 gene from 91 cases of P. " 08/01/2019 - "Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment." 03/01/2018 - "Plasmodium vivax Kelch propeller domain, PvK12, the ortholog of PfK13, could assess resistance towards artemisinin in vivax malaria. " 05/01/2016 - "Early in vitro parasite sensitivity and in vivo efficacy data, together with a long terminal elimination half-life (up to 23 days), suggested that it could be used as monotherapy for uncomplicated falciparum and vivax malaria, but is now marketed as a single-dose, fixed co-formulation with artemisinin in a milligram per kilogram ratio of 1:2.5. " 03/01/2016 - "Monitoring of multidrug-resistant (MDR)falciparum and vivax malaria has recently been included in the Global Plan for Artemisinin Resistance Containment (GPARC) of the Greater Mekong Sub-region, particularly at the Thailand-Cambodia and Thailand-Myanmar borders. "
6.	piperaquineIBA 08/27/2014 - "vivax malaria was accommodated by a constant baseline hazard (8.94 relapses/year) with the addition of a surge function in a fixed 3-week interval and a protective piperaquine effect. " 03/01/2004 - "Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria." 11/27/2022 - "Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia." 01/01/2013 - "This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries. " 01/01/2013 - "Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies."
7.	artenimol (dihydroartemisinin)IBA 11/27/2022 - "Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia." 01/01/2013 - "This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries. " 01/01/2013 - "Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies." 11/01/2011 - "We conducted a randomized controlled study to compare the efficacy and the tolerability of CQ and dihydroartemisinin-piperaquine (DP) in 500 adults and children with acute vivax malaria on the Northwestern border of Thailand. " 01/01/2023 - "Effectiveness of dihydroartemisinin-piperaquine after 10 years as treatment for vivax malaria in Indonesia."
8.	ArtesunateIBA 09/01/2004 - "Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand." 11/01/1998 - "A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria." 09/01/2012 - "Intravenous artesunate for transfusion-transmitted plasmodium vivax malaria in a preterm neonate." 09/01/2004 - "In conclusion, artesunate might be useful in treatment of vivax malaria, causing a good blood schizontocidal effect. " 11/01/1998 - "Artesunate is a suitable initial treatment for vivax malaria, or when the plasmodial species cannot be reliably identified."
9.	Pyrimethamine (Daraprim)FDA Link 12/01/1965 - "The effect of biweekly administration of 50 mg pyrimethamine in prevention of falciparum and vivax malaria." 01/01/1959 - "Pyrimethamine resistance in Plasmodium vivax malaria." 08/01/1953 - "Pyrimethamine daraprim the treatment of vivax malaria." 06/06/1953 - "Pyrimethamine in treatment of vivax malaria; preliminary report." 03/01/2008 - "In Cordoba, the amodiaquine+sulfadoxine-pyrimethamine combination and chloroquine show a high efficacy for the treatment of uncomplicated falciparum and vivax malaria, respectively."
10.	Mefloquine (Lariam)FDA LinkGeneric 05/01/1985 - "A clinical trial of mefloquine in the treatment of Plasmodium vivax malaria." 04/05/1993 - "Group 1: 40 men receiving mefloquine were all protected against falciparum malaria but four (10%) developed vivax malaria. " 01/01/2016 - "A randomized, controlled trial of CQ vs artesunate-mefloquine (AS-MQ) for uncomplicated vivax malaria was conducted in 3 district hospitals in Sabah, Malaysia. " 03/01/2005 - "Despite regular weekly mefloquine prophylaxis (250 mg/d), the patient presented with a first episode of vivax malaria, which was treated by chloroquine alone, then experienced a second crisis in France. " 12/01/1985 - "Forty-six patients with Plasmodium vivax malaria were evaluated for their clinical and parasitological response to the two single doses of mefloquine in comparison with the standard 3-day treatment with chloroquine. "

Therapies and Procedures

1.	Therapeutics 12/01/2011 - "Several clinical trials have repeatedly shown that DHA-PQP is a safe and highly efficacious therapy against uncomplicated Plasmodium falciparum and the asexual stages of Plasmodium vivax malaria. " 01/01/2017 - "These observations have important implications for the epidemiological assessment of vivax malaria, and initiating therapy that is effective against both blood stages and relapses." 01/12/2009 - "The efficacy of standard therapies for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria was assessed in Chumkiri, Kampot Province, Cambodia. " 07/01/2009 - "The rationale, design, and interpretation of clinical trials of therapies for vivax malaria are discussed in the context of the nuance and ambiguity imposed by the hypnozoite. " 10/01/2021 - "We focused interviewed and examined the charts of 28 confirmed vivax malaria patients given malarial therapy for whom daily records were kept from Gimpo-si, Gyeonggido of Korea. "
2.	Secondary Prevention 01/01/2013 - "The spatial extent of Plasmodium vivax malaria overlaps widely with that of G6PD deficiency; unfortunately the only drug licensed for the radical cure and relapse prevention of P. " 10/01/2016 - "Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria. " 01/01/2022 - "Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial." 01/01/2022 - "Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old. " 12/01/2016 - "Tafenoquine is in development as a single-dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. "
3.	Drug Therapy (Chemotherapy) 01/01/2012 - "Development of safe and effective chemotherapies for vivax malaria for the coming decades requires overcoming these challenges." 07/01/2009 - "Fielding new drug therapies against real-world vivax malaria may require a reworking of the strategic framework of drug development, namely, the conception, testing, and evaluation of sets of drugs designed for the cure of both blood and liver asexual stages as well as the sexual blood stages within a single therapeutic regimen." 01/01/2021 - "vivax malaria, we open multiple new avenues to vaccination, chemoprevention, countermeasures against transmission, epidemiology, diagnosis, chemotherapy, and clinical management. " 07/01/2022 - "Because of a 15-year persisted anemia due to misdiagnose of vivax malaria led him to three courses of anticancer chemotherapy and splenectomy. " 05/01/1948 - "Studies on the chemotherapy of the human malarias; method for the quantitative assay of suppressive antimalarial action in vivax malaria."
4.	Chemoprevention 01/01/2020 - "Model simulations indicate that weekly CQ chemoprophylaxis extending over 4 to 12 weeks, starting after the first vivax malaria episode diagnosed in pregnancy, might reduce the risk of P. " 05/01/2014 - "Sensitivity of parasitological tests in imported Plasmodium vivax malaria in adults and impact of chemoprophylaxis and attack type." 01/01/2013 - "Suppressive chemoprophylaxis invites avoidable risk of serious illness caused by Plasmodium vivax malaria." 10/01/2011 - "vivax malaria and/or chemoprophylaxis." 05/14/2011 - "Unexpectedly long incubation period of Plasmodium vivax malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmission area in Brazil."
5.	Aftercare (After-Treatment) 03/01/1997 - "All the 12 cases with vivax malaria were also clinically cured after treatment, but 1 case had relapse 35 days after treatment. " 02/15/2007 - "Progressive alveolar-capillary dysfunction after treatment of vivax malaria is consistent with a greater inflammatory response to a given parasite burden in P. " 01/01/1989 - "In this paper 180 cases of Anyedyushka and Thriteeyaka Vishamajwaras (P.vivax malaria) were studied for various biochemical changes before and after treatment and these changes were correlated with dosha-dushya involvement in these conditions. " 03/01/1981 - "vivax malaria before and after treatment. " 01/01/2016 - "Median parasite clearance times were 45 hours (interquartile range, 42 to 48) in 10 patients with falciparum malaria and 24 hours (interquartile range, 20 to 30) in 10 patients with vivax malaria after treatment with the multiple-dose regimen and 49 hours (interquartile range, 42 to 54) in 21 patients with falciparum malaria after treatment with the single dose. "